Aadi Bioscience, Inc. (AADI)

$12.77

-0.04 (-0.31%)
Rating:
Recommendation:
-
Symbol AADI
Price $12.77
Beta 0.000
Volume Avg. 0.08M
Market Cap 311.525M
Shares () -
52 Week Range 11.0-21.15
1y Target Est -
DCF Unlevered AADI DCF ->
DCF Levered AADI LDCF ->
ROE -46.46% Strong Sell
ROA -32.25% Strong Sell
Operating Margin -
Debt / Equity 14.78% Neutral
P/E 2.70 Buy
P/B 1.61 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AADI news


Healthcare
Biotechnology
NASDAQ Capital Market

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.